REFRAME-O1/ENGOT-OV79/GOG-3086: A PHASE 2/3 OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF LUVELTAMAB TAZEVIBULIN VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY IN RELAPSED PLATINUM-RESISTANT EOC EXPRESSING FOLATE RECEPTOR-ALPHA R. (IGCS 2023) - Oct 25, 2023 - Abstract #TP021 / #1540; P1 | "Part 1 is the dose-optimization stage, with ~50 subjects randomized 1:1 at 4.3 mg/kg Q3W or 5.2 mg/kg Q3W + prophylactic pegfilgrastim for 2 cycles followed by 4.3 mg/kg Q3W. Key exclusion criteria: primary platinum refractory disease and prior treatment with a FolRα ADC or ADC-containing tubulin inhibitor. Current Trial Status: Currently enrolling"
Clinical • P2/3 data • Oncology • Ovarian Cancer • Solid Tumor • FOLR1 • PROC
|
|
Wendel Naumann1; Antonio González-Martín2; Thomas Herzog3; Robert Coleman4; Isabelle RayCoquard5; Rowan Miller , Lin Lu7; Hatem Dokainish8; Craig Berman9; Ana Oaknin10
|